Comparing Innovation Spending: Lantheus Holdings, Inc. and Alpine Immune Sciences, Inc.

R&D Spending: Alpine vs. Lantheus - A Decade of Innovation

__timestampAlpine Immune Sciences, Inc.Lantheus Holdings, Inc.
Wednesday, January 1, 20141219954713673000
Thursday, January 1, 20151605400014358000
Friday, January 1, 20162331600012203000
Sunday, January 1, 20171062600018125000
Monday, January 1, 20182897000017071000
Tuesday, January 1, 20193584700020018000
Wednesday, January 1, 20202718500032788000
Friday, January 1, 20215874200044966000
Saturday, January 1, 202270243000311681000
Sunday, January 1, 20238090400077707000
Loading chart...

Unlocking the unknown

Innovation Spending: A Tale of Two Companies

In the ever-evolving landscape of biotechnology and pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Alpine Immune Sciences, Inc. and Lantheus Holdings, Inc. have demonstrated contrasting approaches to R&D investment.

From 2014 to 2023, Alpine Immune Sciences, Inc. increased its R&D expenses by over 560%, reflecting a robust commitment to pioneering new therapies. In contrast, Lantheus Holdings, Inc. experienced a more volatile R&D spending pattern, with a significant spike in 2022, where expenses surged by over 600% compared to the previous year. This fluctuation highlights Lantheus's strategic focus on targeted innovation bursts.

As these companies navigate the competitive biotech sector, their R&D investments will continue to shape their future trajectories, offering insights into their strategic priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025